Completed PHASE2 INTERVENTIONAL NCT00034151

Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer

A Phase IIA Evaluation of Safety and Efficacy of Weekly S-8184 Paclitaxel Injectable Emulsion in Second Line Treatment of Stage III or IV Platinum Resistant Ovarian Cancer or Primary Peritoneal Carcinoma

Sponsor: Achieve Life Sciences

Conditions Ovarian Cancer

Interventions S-8184 Paclitaxel Injectable Emulsion

Updated 7 times since 2017 Last updated: Jun 2, 2009 Started: Mar 31, 2002 Primary completion: Sep 30, 2007 Completion: Sep 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00034151, this PHASE2 trial focuses on Ovarian Cancer and remains completed. Sponsored by Achieve Life Sciences, it has been updated 7 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Sep 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Sep 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Achieve Life Sciences

Data source: Achieve Life Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.